388 results on '"Timmers, Henri J. L. M."'
Search Results
2. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement
3. Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort
4. [18F]FDG-PET/CT radiomics for the identification of genetic clusters in pheochromocytomas and paragangliomas
5. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants
6. Predicting surgical outcome in posterior retroperitoneoscopic adrenalectomy with the aid of a preoperative nomogram
7. Diagnosis and management of urinary bladder paragangliomas: A Sino‐American‐European retrospective observational study
8. Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma
9. Chronic postsurgical pain after minimally invasive adrenalectomy: prevalence and impact on quality of life
10. Identification of Succinate Dehydrogenase Gene Variant Carriers by Blood Biomarkers.
11. Extensive patient-to-patient single nucleus transcriptome heterogeneity in pheochromocytomas and paragangliomas.
12. Characterisation of an Adult Zebrafish Model for SDHB -Associated Phaeochromocytomas and Paragangliomas.
13. Imaging of Pheochromocytomas and Paragangliomas
14. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers
15. Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
16. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma - A retrospective multi-center cohort study
17. Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion
18. Radionuclide Imaging of Pheochromocytoma and Paraganglioma in the Era of Multi-omics
19. Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma
20. Correction to: A comparison of high‑throughput plasma NMR protocols for comparative untargeted metabolomics
21. A comparison of high-throughput plasma NMR protocols for comparative untargeted metabolomics
22. Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas.
23. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
24. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
25. Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine
26. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma
27. Extensive patient-to-patient single nucleus transcriptome heterogeneity in pheochromocytomas and paragangliomas
28. Preanalytical Pitfalls in Untargeted Plasma Nuclear Magnetic Resonance Metabolomics of Endocrine Hypertension
29. Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study
30. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas
31. Feasibility of a wait‐and‐scan period as initial management strategy for head and neck paraganglioma
32. Radionuclide Imaging of Pheochromocytoma and Paraganglioma in the Era of Multi-omics
33. Functional and in silico assessment of MAX variants of unknown significance
34. Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma
35. Multidisciplinary integrated care pathway for von Hippel–Lindau disease
36. Influence of Receptor Polymorphisms on the Response to α-Adrenergic Receptor Blockers in Pheochromocytoma Patients
37. Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine
38. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
39. Diagnosis and Management of Urinary Bladder Paragangliomas: A Retrospective International Multicenter Study
40. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma
41. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHDpathogenic variants
42. Targeting the Redox Balance Pathway Using Ascorbic Acid in sdhb Zebrafish Mutant Larvae
43. Circulating adrenomedullin and B-type natriuretic peptide do not predict blood pressure fluctuations during pheochromocytoma resection: a cross-sectional study
44. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma
45. [18F]FDG-PET/CT radiomics for the identification of genetic clusters in pheochromocytomas and paragangliomas.
46. Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma
47. The Influence of the Exclusion of Central Necrosis on [18F]FDG PET Radiomic Analysis
48. Management of phaeochromocytoma and paraganglioma in patients with germline SDHBpathogenic variants: an international expert Consensus statement
49. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X
50. Response to letter to the editor: 'Approach to the Patient: Perioperative Management of the Patient With Pheochromocytoma or Sympathetic Paraganglioma'
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.